Amiodarone and cardiac arrest: Systematic review and meta-analysis

Laina, Ageliki; Karlis, George; Liakos, Aris; Georgiopoulos, Georgios; Oikonomou, Dimitrios; Kouskouni, Evangelia; Chalkias, Athanasios; Xanthos, Theodoros

doi:10.1016/j.ijcard.2016.07.138

Cited by 24 publications

(14 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2016, Laina et al analyzed the findings of 1,663 studies conducted with amiodarone and found that amiodarone significantly increased short-term survival rate (OR = 1.42 p = 0.015). Findings with reference to the long-term effects of amiodarone affecting the neurological outcome primarily are not straightforward, although encouraging when compared to other antiarrhythmic agents (Laina et al, 2016;Karlis and Afantenou, 2018). In 2018, American Heart Association (AHA) recommended the further application of amiodarone or lidocaine in the case of VF/pVT due to their short-term positive effects (Panchal et al, 2018).…”

Section: Cpc Levelmentioning

confidence: 99%

Handling of Ventricular Fibrillation in the Emergency Setting

et al. 2020

View full text Add to dashboard Cite

Ventricular fibrillation (VF) and sudden cardiac death (SCD) are predominantly caused by channelopathies and cardiomyopathies in youngsters and coronary heart disease in the elderly. Temporary factors, e.g., electrolyte imbalance, drug interactions, and substance abuses may play an additive role in arrhythmogenesis. Ectopic automaticity, triggered activity, and reentry mechanisms are known as important electrophysiological substrates for VF determining the antiarrhythmic therapies at the same time. Emergency need for electrical cardioversion is supported by the fact that every minute without defibrillation decreases survival rates by approximately 7%-10%. Thus, early defibrillation is an essential part of antiarrhythmic emergency management. Drug therapy has its relevance rather in the prevention of sudden cardiac death, where early recognition and treatment of the underlying disease has significant importance. Cardioprotective and antiarrhythmic effects of beta blockers in patients predisposed to sudden cardiac death were highlighted in numerous studies, hence nowadays these drugs are considered to be the cornerstones of the prevention and treatment of life-threatening ventricular arrhythmias. Nevertheless, other medical therapies have not been proven to be useful in the prevention of VF. Although amiodarone has shown positive results occasionally, this was not demonstrated to be consistent. Furthermore, the potential proarrhythmic effects of drugs may also limit their applicability. Based on these unfavorable observations we highlight the importance of arrhythmia prevention, where echocardiography, electrocardiography and laboratory testing play a significant role even in the emergency setting. In the following we provide a summary on the latest developments on cardiopulmonary resuscitation, and the evaluation and preventive treatment possibilities of patients with increased susceptibility to VF and SCD.

show abstract

Section: Cpc Levelmentioning

confidence: 99%

Handling of Ventricular Fibrillation in the Emergency Setting

et al. 2020

View full text Add to dashboard Cite

show abstract

“…After publication of the results of the ROC‐ALPS study, two systematic reviews with meta‐analyses were published in 2016 [33, 34]. Laina et al [34] reported that amiodarone therapy significantly improved survival to hospital admission (OR 1.402; 95% CI 1.068–1.840; Z = 2.43; p = 0.015), but neither survival to hospital discharge (RR 0.850; 95% CI 0.631–1.144; Z = 1.07; p = 0.284) nor neurological outcome (OR 1.114; 95% CI 0.923–1.345; Z = 1.12; p = 0.475) were significantly improved by amiodarone therapy compared with placebo or nifekalant therapy.…”

Section: Recent Systematic Review and Meta‐analysesmentioning

confidence: 99%

Antiarrhythmic drugs for out-of-hospital cardiac arrest with refractory ventricular fibrillation

Tagami

Yasunaga

2017

Crit Care

View full text Add to dashboard Cite

show abstract

“…Laina et al [34] reported that amiodarone therapy significantly improved survival to hospital admission (OR 1.402; 95% CI 1.068-1.840; Z = 2.43; p = 0.015), but neither survival to hospital discharge (RR 0.850; 95% CI 0.631-1.144; Z = 1.07; p = 0.284) nor neurological outcome (OR 1.114; 95% CI 0.923-1.345; Z = 1.12; p = 0.475) were significantly improved by amiodarone therapy compared with placebo or nifekalant therapy. Sanfilippo et al [33] These recent four systematic reviews with meta-analyses suggested that amiodarone, lidocaine and nifekalant therapies equally improved survival to hospital admission as compared with placebo.…”

Section: Recent Systematic Review and Meta-analysesmentioning

confidence: 99%